Contact Us | Canalevia

top of page

VETERINARY PROFESSIONALS
ORDER NOW
EVENTS
DOG OWNERS
ABOUT US
MEDIA MENTIONS

CONTACT US

I am a *

Veterinarian

Distributor

Dog Owner

Other

Name

Name of Organization

Title

Email

Phone

Address

Address Line 2

City

State

Zip Code

How did you hear about us?

Message

By clicking submit, you are agreeing to receive future communications about Canalevia®-CA1 from Jaguar Animal Health.

Thanks for submitting!

200 Pine Street, Suite 600

San Francisco, CA 94104

Jaguar Animal Health

1 (877) 787-3001

info@canalevia.com

Contact Us

1 (877) 787-3001

info@canalevia.com

Location

Jaguar Animal Health

200 Pine Street, Suite 600

San Francisco, CA 94104

Join Our Mailing List

Investor Relations

Partnering with Canalevia-CA1

Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-552.

CAUTION: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian. It is a violation of Federal Law to use this product other than as directed in the labeling.

IMPORTANT SAFETY INFORMATION

For oral use in dogs only. Not for use in humans. Keep Canalevia®-CA1 (crofelemer delayed-release tablets) in a secure location out of reach of children and other animals. Consult a physician in case of accidental ingestion by humans. Do not use in dogs that have a known hypersensitivity to crofelemer. Prior to using Canalevia-CA1, rule out infectious etiologies of diarrhea. Canalevia-CA1 is a conditionally approved drug indicated for the treatment of chemotherapy-induced diarrhea in dogs. The most common adverse reactions included decreased appetite, decreased activity, dehydration, abdominal pain, and vomiting.

Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Use only as directed. It is a violation of Federal law to use this product other than as directed in the labeling. Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-552.

bottom of page